1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Constrained Peptide Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Cyclic Peptides
1.2.3 Disulfide-Rich Peptides (DRPs)
1.3 Market by Application
1.3.1 Global Constrained Peptide Drugs Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Institute of Biology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Constrained Peptide Drugs Market Perspective (2017-2028)
2.2 Constrained Peptide Drugs Growth Trends by Region
2.2.1 Constrained Peptide Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Constrained Peptide Drugs Historic Market Size by Region (2017-2022)
2.2.3 Constrained Peptide Drugs Forecasted Market Size by Region (2023-2028)
2.3 Constrained Peptide Drugs Market Dynamics
2.3.1 Constrained Peptide Drugs Industry Trends
2.3.2 Constrained Peptide Drugs Market Drivers
2.3.3 Constrained Peptide Drugs Market Challenges
2.3.4 Constrained Peptide Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Constrained Peptide Drugs Players by Revenue
3.1.1 Global Top Constrained Peptide Drugs Players by Revenue (2017-2022)
3.1.2 Global Constrained Peptide Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Constrained Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Constrained Peptide Drugs Revenue
3.4 Global Constrained Peptide Drugs Market Concentration Ratio
3.4.1 Global Constrained Peptide Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Constrained Peptide Drugs Revenue in 2021
3.5 Constrained Peptide Drugs Key Players Head office and Area Served
3.6 Key Players Constrained Peptide Drugs Product Solution and Service
3.7 Date of Enter into Constrained Peptide Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Constrained Peptide Drugs Breakdown Data by Type
4.1 Global Constrained Peptide Drugs Historic Market Size by Type (2017-2022)
4.2 Global Constrained Peptide Drugs Forecasted Market Size by Type (2023-2028)
5 Constrained Peptide Drugs Breakdown Data by Application
5.1 Global Constrained Peptide Drugs Historic Market Size by Application (2017-2022)
5.2 Global Constrained Peptide Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Constrained Peptide Drugs Market Size (2017-2028)
6.2 North America Constrained Peptide Drugs Market Size by Country (2017-2022)
6.3 North America Constrained Peptide Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Constrained Peptide Drugs Market Size (2017-2028)
7.2 Europe Constrained Peptide Drugs Market Size by Country (2017-2022)
7.3 Europe Constrained Peptide Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Constrained Peptide Drugs Market Size (2017-2028)
8.2 Asia-Pacific Constrained Peptide Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Constrained Peptide Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Constrained Peptide Drugs Market Size (2017-2028)
9.2 Latin America Constrained Peptide Drugs Market Size by Country (2017-2022)
9.3 Latin America Constrained Peptide Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Constrained Peptide Drugs Market Size (2017-2028)
10.2 Middle East & Africa Constrained Peptide Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Constrained Peptide Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Aileron Therapeutics, Inc
11.1.1 Aileron Therapeutics, Inc Company Detail
11.1.2 Aileron Therapeutics, Inc Business Overview
11.1.3 Aileron Therapeutics, Inc Constrained Peptide Drugs Introduction
11.1.4 Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
11.1.5 Aileron Therapeutics, Inc Recent Development
11.2 Bicycle Therapeutics, PLC
11.2.1 Bicycle Therapeutics, PLC Company Detail
11.2.2 Bicycle Therapeutics, PLC Business Overview
11.2.3 Bicycle Therapeutics, PLC Constrained Peptide Drugs Introduction
11.2.4 Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2017-2022)
11.2.5 Bicycle Therapeutics, PLC Recent Development
11.3 Polyphor Limited
11.3.1 Polyphor Limited Company Detail
11.3.2 Polyphor Limited Business Overview
11.3.3 Polyphor Limited Constrained Peptide Drugs Introduction
11.3.4 Polyphor Limited Revenue in Constrained Peptide Drugs Business (2017-2022)
11.3.5 Polyphor Limited Recent Development
11.4 Protagonist Therapeutics, Inc
11.4.1 Protagonist Therapeutics, Inc Company Detail
11.4.2 Protagonist Therapeutics, Inc Business Overview
11.4.3 Protagonist Therapeutics, Inc Constrained Peptide Drugs Introduction
11.4.4 Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
11.4.5 Protagonist Therapeutics, Inc Recent Development
11.5 Santhera Pharmaceuticals Holding
11.5.1 Santhera Pharmaceuticals Holding Company Detail
11.5.2 Santhera Pharmaceuticals Holding Business Overview
11.5.3 Santhera Pharmaceuticals Holding Constrained Peptide Drugs Introduction
11.5.4 Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2017-2022)
11.5.5 Santhera Pharmaceuticals Holding Recent Development
11.6 Union Chimique Belge S.A. (UCB)
11.6.1 Union Chimique Belge S.A. (UCB) Company Detail
11.6.2 Union Chimique Belge S.A. (UCB) Business Overview
11.6.3 Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Introduction
11.6.4 Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2017-2022)
11.6.5 Union Chimique Belge S.A. (UCB) Recent Development
11.7 Pepscan Therapeutics B.V.
11.7.1 Pepscan Therapeutics B.V. Company Detail
11.7.2 Pepscan Therapeutics B.V. Business Overview
11.7.3 Pepscan Therapeutics B.V. Constrained Peptide Drugs Introduction
11.7.4 Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2017-2022)
11.7.5 Pepscan Therapeutics B.V. Recent Development
11.8 Pepticom Ltd.
11.8.1 Pepticom Ltd. Company Detail
11.8.2 Pepticom Ltd. Business Overview
11.8.3 Pepticom Ltd. Constrained Peptide Drugs Introduction
11.8.4 Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2017-2022)
11.8.5 Pepticom Ltd. Recent Development
11.9 PeptiDream, Inc.
11.9.1 PeptiDream, Inc. Company Detail
11.9.2 PeptiDream, Inc. Business Overview
11.9.3 PeptiDream, Inc. Constrained Peptide Drugs Introduction
11.9.4 PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2017-2022)
11.9.5 PeptiDream, Inc. Recent Development
11.10 CPC Scientific Inc.
11.10.1 CPC Scientific Inc. Company Detail
11.10.2 CPC Scientific Inc. Business Overview
11.10.3 CPC Scientific Inc. Constrained Peptide Drugs Introduction
11.10.4 CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2017-2022)
11.10.5 CPC Scientific Inc. Recent Development
11.11 Creative Peptides
11.11.1 Creative Peptides Company Detail
11.11.2 Creative Peptides Business Overview
11.11.3 Creative Peptides Constrained Peptide Drugs Introduction
11.11.4 Creative Peptides Revenue in Constrained Peptide Drugs Business (2017-2022)
11.11.5 Creative Peptides Recent Development
11.12 Bio-Synthesis Inc
11.12.1 Bio-Synthesis Inc Company Detail
11.12.2 Bio-Synthesis Inc Business Overview
11.12.3 Bio-Synthesis Inc Constrained Peptide Drugs Introduction
11.12.4 Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
11.12.5 Bio-Synthesis Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Constrained Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Cyclic Peptides
Table 3. Key Players of Disulfide-Rich Peptides (DRPs)
Table 4. Global Constrained Peptide Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 5. Global Constrained Peptide Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Constrained Peptide Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Constrained Peptide Drugs Market Share by Region (2017-2022)
Table 8. Global Constrained Peptide Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Constrained Peptide Drugs Market Share by Region (2023-2028)
Table 10. Constrained Peptide Drugs Market Trends
Table 11. Constrained Peptide Drugs Market Drivers
Table 12. Constrained Peptide Drugs Market Challenges
Table 13. Constrained Peptide Drugs Market Restraints
Table 14. Global Constrained Peptide Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Constrained Peptide Drugs Market Share by Players (2017-2022)
Table 16. Global Top Constrained Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Constrained Peptide Drugs as of 2021)
Table 17. Ranking of Global Top Constrained Peptide Drugs Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Constrained Peptide Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Constrained Peptide Drugs Product Solution and Service
Table 21. Date of Enter into Constrained Peptide Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Constrained Peptide Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Constrained Peptide Drugs Revenue Market Share by Type (2017-2022)
Table 25. Global Constrained Peptide Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Constrained Peptide Drugs Revenue Market Share by Type (2023-2028)
Table 27. Global Constrained Peptide Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Constrained Peptide Drugs Revenue Market Share by Application (2017-2022)
Table 29. Global Constrained Peptide Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Constrained Peptide Drugs Revenue Market Share by Application (2023-2028)
Table 31. North America Constrained Peptide Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 32. North America Constrained Peptide Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 33. Europe Constrained Peptide Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 34. Europe Constrained Peptide Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 35. Asia-Pacific Constrained Peptide Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 36. Asia-Pacific Constrained Peptide Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 37. Latin America Constrained Peptide Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 38. Latin America Constrained Peptide Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 39. Middle East & Africa Constrained Peptide Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 40. Middle East & Africa Constrained Peptide Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 41. Aileron Therapeutics, Inc Company Detail
Table 42. Aileron Therapeutics, Inc Business Overview
Table 43. Aileron Therapeutics, Inc Constrained Peptide Drugs Product
Table 44. Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 45. Aileron Therapeutics, Inc Recent Development
Table 46. Bicycle Therapeutics, PLC Company Detail
Table 47. Bicycle Therapeutics, PLC Business Overview
Table 48. Bicycle Therapeutics, PLC Constrained Peptide Drugs Product
Table 49. Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 50. Bicycle Therapeutics, PLC Recent Development
Table 51. Polyphor Limited Company Detail
Table 52. Polyphor Limited Business Overview
Table 53. Polyphor Limited Constrained Peptide Drugs Product
Table 54. Polyphor Limited Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 55. Polyphor Limited Recent Development
Table 56. Protagonist Therapeutics, Inc Company Detail
Table 57. Protagonist Therapeutics, Inc Business Overview
Table 58. Protagonist Therapeutics, Inc Constrained Peptide Drugs Product
Table 59. Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 60. Protagonist Therapeutics, Inc Recent Development
Table 61. Santhera Pharmaceuticals Holding Company Detail
Table 62. Santhera Pharmaceuticals Holding Business Overview
Table 63. Santhera Pharmaceuticals Holding Constrained Peptide Drugs Product
Table 64. Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 65. Santhera Pharmaceuticals Holding Recent Development
Table 66. Union Chimique Belge S.A. (UCB) Company Detail
Table 67. Union Chimique Belge S.A. (UCB) Business Overview
Table 68. Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Product
Table 69. Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 70. Union Chimique Belge S.A. (UCB) Recent Development
Table 71. Pepscan Therapeutics B.V. Company Detail
Table 72. Pepscan Therapeutics B.V. Business Overview
Table 73. Pepscan Therapeutics B.V. Constrained Peptide Drugs Product
Table 74. Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 75. Pepscan Therapeutics B.V. Recent Development
Table 76. Pepticom Ltd. Company Detail
Table 77. Pepticom Ltd. Business Overview
Table 78. Pepticom Ltd. Constrained Peptide Drugs Product
Table 79. Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 80. Pepticom Ltd. Recent Development
Table 81. PeptiDream, Inc. Company Detail
Table 82. PeptiDream, Inc. Business Overview
Table 83. PeptiDream, Inc. Constrained Peptide Drugs Product
Table 84. PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 85. PeptiDream, Inc. Recent Development
Table 86. CPC Scientific Inc. Company Detail
Table 87. CPC Scientific Inc. Business Overview
Table 88. CPC Scientific Inc. Constrained Peptide Drugs Product
Table 89. CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 90. CPC Scientific Inc. Recent Development
Table 91. Creative Peptides Company Detail
Table 92. Creative Peptides Business Overview
Table 93. Creative Peptides Constrained Peptide DrugsProduct
Table 94. Creative Peptides Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 95. Creative Peptides Recent Development
Table 96. Bio-Synthesis Inc Company Detail
Table 97. Bio-Synthesis Inc Business Overview
Table 98. Bio-Synthesis Inc Constrained Peptide DrugsProduct
Table 99. Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million)
Table 100. Bio-Synthesis Inc Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Constrained Peptide Drugs Market Share by Type: 2021 VS 2028
Figure 2. Cyclic Peptides Features
Figure 3. Disulfide-Rich Peptides (DRPs) Features
Figure 4. Global Constrained Peptide Drugs Market Share by Application in 2021 & 2028
Figure 5. Hospital Case Studies
Figure 6. Institute of Biology Case Studies
Figure 7. Others Case Studies
Figure 8. Constrained Peptide Drugs Report Years Considered
Figure 9. Global Constrained Peptide Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Constrained Peptide Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Constrained Peptide Drugs Market Share by Region: 2021 VS 2028
Figure 12. Global Constrained Peptide Drugs Market Share by Players in 2021
Figure 13. Global Top Constrained Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Constrained Peptide Drugs as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Constrained Peptide Drugs Revenue in 2021
Figure 15. North America Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 16. North America Constrained Peptide Drugs Market Share by Country (2017-2028)
Figure 17. United States Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. Canada Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Europe Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Constrained Peptide Drugs Market Share by Country (2017-2028)
Figure 21. Germany Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. France Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. U.K. Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Italy Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Russia Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Nordic Countries Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Constrained Peptide Drugs Market Share by Region (2017-2028)
Figure 29. China Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Japan Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. South Korea Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Southeast Asia Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. India Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Australia Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Latin America Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Constrained Peptide Drugs Market Share by Country (2017-2028)
Figure 37. Mexico Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Brazil Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Middle East & Africa Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Constrained Peptide Drugs Market Share by Country (2017-2028)
Figure 41. Turkey Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Saudi Arabia Constrained Peptide Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Aileron Therapeutics, Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 44. Bicycle Therapeutics, PLC Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 45. Polyphor Limited Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 46. Protagonist Therapeutics, Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 47. Santhera Pharmaceuticals Holding Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 48. Union Chimique Belge S.A. (UCB) Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 49. Pepscan Therapeutics B.V. Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 50. Pepticom Ltd. Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 51. PeptiDream, Inc. Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 52. CPC Scientific Inc. Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 53. Creative Peptides Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 54. Bio-Synthesis Inc Revenue Growth Rate in Constrained Peptide Drugs Business (2017-2022)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
